SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria

Pharmacogenomics. 2017 Oct;18(15):1393-1400. doi: 10.2217/pgs-2017-0077. Epub 2017 Oct 4.

Abstract

Aim: The association of transporters gene polymorphisms with chloroquine/primaquine malaria treatment response was investigated in a Brazilian population.

Patients & methods: Totally, 164 Plasmodium vivax malaria infected patients were included. Generalized estimating equations were performed to determine gene influences on parasitemia and/or gametocytemia clearance over treatment time.

Results: Significant interaction between SLCO2B1 genotypes and treatment over time for parasitemia clearance rate on day 2 were observed (p FDR = 0.002). SLCO1A2 and SLCO1B1 gene treatment over time interactions were associated with gametocytemia clearance rate (p FDR = 0.018 and p FDR = 0.024). ABCB1, ABCC4 and SLCO1B3 were not associated with treatment response.

Conclusion: The present work presents the first pharmacogenetic report of an association between chloroquine/primaquine responses with OATP transporters.

Keywords: chloroquine and primaquine; malaria; transporter genes.

MeSH terms

  • Adult
  • Antimalarials / therapeutic use
  • Brazil
  • Chloroquine / therapeutic use*
  • Drug Therapy, Combination / methods
  • Female
  • Genotype
  • Humans
  • Liver-Specific Organic Anion Transporter 1 / genetics*
  • Malaria, Vivax / drug therapy
  • Malaria, Vivax / genetics*
  • Male
  • Organic Anion Transporters / genetics*
  • Parasitemia / drug therapy
  • Parasitemia / genetics
  • Plasmodium vivax / drug effects
  • Polymorphism, Genetic / genetics*
  • Primaquine / therapeutic use*
  • Treatment Outcome

Substances

  • Antimalarials
  • Liver-Specific Organic Anion Transporter 1
  • Organic Anion Transporters
  • SLCO1A2 protein, human
  • SLCO1B1 protein, human
  • SLCO2B1 protein, human
  • Chloroquine
  • Primaquine